Crispr Therapeutics AG (CRSP) is around the top of the Biotechnology industry according to InvestorsObserver. CRSP received an overall rating of 61, which means that it scores higher than 61 percent of all stocks. Crispr Therapeutics AG also achieved a score of 70 in the Biotechnology industry, putting it above 70 percent of Biotechnology stocks. Biotechnology is ranked 23 out of the 148 industries.
What do These Ratings Mean?
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.
What's Happening With Crispr Therapeutics AG Stock Today?
Crispr Therapeutics AG (CRSP) stock is trading at $100.62 as of 10:53 AM on Friday, Oct 9, a rise of $5.22, or 5.48% from the previous closing price of $95.39. The stock has traded between $96.33 and $100.88 so far today. Volume today is low. So far 405,219 shares have traded compared to average volume of 726,789 shares.